Spondyloarthropathies
News from the FDA/CDC
FDA Approves 10th Humira Biosimilar, With Interchangeability
Adalimumab-ryvk (Simlandi) is the first adalimumab biosimilar in a high-concentration formulation to receive interchangeability status from the...
From the Journals
Ixekizumab’s Final Safety Results Reported Across 25 Trials in Psoriasis, PsA, Axial SpA
Final safety results from 25 randomized clinical trials were consistent with previous reports at up to 6 years’ follow-up.
From the Journals
Comorbidities and Disease Type Weigh Heavily in Pregnancy Outcomes of Immune-Mediated Inflammatory Diseases
After controlling for other chronic conditions, certain immune-mediated inflammatory diseases were not associated with an increased risk for poor...
Latest News
Utility of NSAID Response Called Into Question for Longstanding AxSpA
New study finds no difference in long-term back pain from axSpA treated with NSAIDs and non-axSpA back pain.
From the Journals
A Paradox? Higher Male Fertility Seen With Inflammatory Arthritis
In a population-based study, male patients with inflammatory joint disease had more children and were less likely to be childless than were...
From the Journals
Tool Uses Genetics to Assist With Diagnosis of Early Inflammatory Arthritis
The tool may aid in accelerating accurate diagnosis and getting patients on the right treatments earlier.
Feature
What Is the Best Way to Manage Axial Spondyloarthritis in Primary Care?
While awaiting referral to a rheumatologist, PCPs can aid in management of axial spondyloarthritis.
Conference Coverage
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...
Latest News
First referral guide issued for axial spondyloarthritis
The draft recommendations are a “good first step,” but more awareness around axial spondyloarthritis in the nonrheumatology community is also...
Conference Coverage
TNF blockers not associated with poorer pregnancy outcomes
Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal...
News from the FDA/CDC
Approximately 20% of U.S. adults are diagnosed with arthritis
New data show disproportionate arthritis prevalence among women, veterans, non-Hispanic White individuals, and those aged 45 years and older.